SHPH Shuttle Pharmaceuticals Holdings, Inc.
Listings ·
Nasdaq says Shuttle no longer meets Listing Rule 5250(c)(1) because its quarterly report for the period ended June 30, 2026 is late. A plan to regain compliance is due October 27, 2026.
The merger is backed by an $11 million private placement that Shuttle expected to close on May 4, 2026.
Shuttle reported stockholders' equity of $1,394,161 against Nasdaq's $2,500,000 minimum. Nasdaq staff will keep monitoring, and delisting is possible if compliance is not shown in the next periodic report.
Shuttle Pharmaceuticals priced 19,166,667 shares, or pre-funded warrants, at $0.30 per share for gross proceeds expected to be about $5.75 million. WestPark Capital, Inc. is the sole book-runner on a firm commitment basis.
Shuttle paid Alto Opportunity Master Fund $75,000 under an amendment signed February 26, 2025. The holder gave up its right to buy up to $10 million of additional notes and warrants, and waived its right to join a contemplated registered offering.
Shuttle Pharmaceuticals Holdings, Inc. acquired substantially all of the assets and liabilities of Molecule.ai on November 21, 2025. Molecule.ai is a pharmaceutical software company building an artificial intelligence platform for molecular discovery and early-stage drug development. The platform performs molecular property prediction, cross-molecule and cross-property evaluation, and prediction reasoning that produces structured molecular insights, using transformer-based models and an LLM-based reasoning module. The company is developing a module to evaluate chemical-protein interaction likelihoods, biological context reasoning and an autonomous AI agent designed to plan research steps and route them to the appropriate tools. On November 20, 2025, the company committed to a plan to wind down the clinical trials of Ropidoxuridine, its lead product candidate, and says it is still evaluating the business impacts of that discontinuance and of the Molecule.ai acquisition. Research and development expenses for Ropidoxuridine, before contract reimbursements, were $4,054,831 for fiscal 2025 and $3,618,796 for fiscal 2024. The company had two full-time employees as of the report date. It received Nasdaq notices about its stockholders' equity and minimum bid price, and effected a 1-for-25 reverse stock split on June 16, 2025.
| Product or program | What it is | Stage |
|---|---|---|
| Molecule.ai platform | AI platform for molecular property prediction and structured molecular reasoning | Acquired November 21, 2025; new modules in development |
| Autonomous AI agent | Agent to plan research steps, route tasks to tools and iterate on results | In development |
| Ropidoxuridine | Lead product candidate whose clinical trials are being wound down | Wind-down of clinical trials committed November 20, 2025 |
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $4.1 million | $3.6 million |
| Net income (loss) | -$11.7 million | -$9.1 million |
| Cash from operations | -$9.5 million | -$7.3 million |
| Cash and equivalents | $334,005 | $1.9 million |
Our latest story on this, dated Nov 17, 2025: "Shuttle Pharmaceuticals believes $2.5 million private placement restored Nasdaq equity compliance". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated May 1, 2026: "Shuttle Pharmaceuticals agrees to merge with United Dogecoin". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Aug 28, 2026: "Shuttle Pharmaceuticals gets Nasdaq deficiency notice over late Form 10-Q". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated May 1, 2026: "Shuttle Pharmaceuticals agrees to merge with United Dogecoin". The story links the filing or release it is based on. Read the story.
Shuttle Pharmaceuticals Holdings, Inc. trades under the ticker SHPH on NASDAQ.
Shuttle Pharmaceuticals Holdings, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Shuttle Pharmaceuticals Holdings, Inc. is 1757499. Its filings are on SEC EDGAR.
4,764,696 shares as of 2026-09-21, per the cover page of its 10-Q filed 2026-09-24.
Our directory records Shuttle Pharmaceuticals Holdings, Inc. under United States.
Our directory classifies Shuttle Pharmaceuticals Holdings, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Shuttle Pharmaceuticals Holdings, Inc. is US8256935003.
aibio.space lists Shuttle Pharmaceuticals Holdings, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Shuttle Pharmaceuticals Holdings, Inc. acquired substantially all of the assets and liabilities of Molecule.ai on November 21, 2025. Molecule.ai is a pharmaceutical software company building an artificial intelligence platform for molecular discovery and early-stage drug development.
Molecule.ai platform: AI platform for molecular property prediction and structured molecular reasoning Stage: Acquired November 21, 2025; new modules in development.
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,9.01). Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,7.01,9.01). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Filed a registration statement for a share offering. SEC Form S-1. Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,9.01). Source
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,2.01,3.02,9.01). Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 1.01,1.02,2.05,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.01,1.02,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.02,5.07). Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 1.01,3.01,7.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,9.01). Source
Filed a registration statement for a share offering. SEC Form S-1. Source
Filed a registration statement for a share offering. SEC Form S-1. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,8.01,9.01). Source
Reported a financing. SEC Form 424B4. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio